The authors would like to thank the entire GAITWAY tumor board for their input and assistance on this case.
Dr. Park is a paid member of the scientific advisory boards of Horizon Discovery, LTD and Loxo Oncology, has ownership interest in Loxo Oncology, and received research support from Genomic Health, Inc. and Foundation Medicine, Inc. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, Dr. Park and Dr. Lauring are entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by the Johns Hopkins University, in accordance with its conflict of interest policies. None of these conflicts pertains to this manuscript. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
This work was supported in part by The Avon Foundation (B.H.P. and J.L.), NIH CA009071 (K.C. and B.H.P.), and the Sandy Garcia Charitable Foundation (D.C. and B.B.). Support was also received by NIH P30 CA006973, the Commonwealth Foundation, the Santa Fe Foundation, the Breast Cancer Research Foundation (B.H.P.), the ME Foundation, and the Augustine Fellowship (W.B.D.). None of the funding sources influenced the design, interpretation, or submission of this manuscript.
See JNCCN.org for supplemental online content.
Jones S, Anagnostou V, Lytle K et al. . Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7:283ra53.
Verstovsek S, Kantarjian H, Mesa RA et al. . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117–1127.
Etheridge SL, Cosgrove ME, Sangkhae V et al. . A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 2014;123:1059–1068.
Marty C, Saint-Martin C, Pecquet C et al. . Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014;123:1372–1383.
Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med 2012;366:967–969.
Thiede C, Prange-Krex G, Freiberg-Richter J et al. . Buccal swabs but not mouthwash samples can be used to obtain pretransplant DNA fingerprints from recipients of allogeneic bone marrow transplants. Bone Marrow Transplant 2000;25:575–577.
Tsiatis AC, Norris-Kirby A, Rich RG et al. . Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010;12:425–432.